CDKN2A and pancreatic neoplasm: Pathogenic germline CDKN2A variants have been identified in up to 3.3% patients with familial pancreatic cancer and up to 2.6% of patients with PDAC unselected for family history or without a family history of PDAC (Brand et al., 2018; Chaffee et al., 2018; Hu et al., 2018; Kimura et al., 2021; Lowery et al., 2018; McWilliams et al., 2018; McWilliams et al., 2011; Roberts et al., 2016; Shindo et al., 2017; Singhi et al., 2019; Zhen et al., 2015).